Table 2.
Distribution of CMV antibody profile in healthy individuals, IIM, MDA5+ DM, and MDA5− IIM patients.
| Antibodies tested | Healthy controls (n = 50) | Total IMM (n = 204) | P-value | MDA5+ DM (n = 89) | MDA5− IIM (n = 115) | P-value |
|---|---|---|---|---|---|---|
| CMV-IgM, U/ ml | 0 (0–0) | 6 (5–11) | 0.000* | 8 (5–14) | 6 (5–10) | 0.039* |
| % positive | 0% | 8.3% | 0.050# | 13.5% | 4.3% | 0.019# |
| CMV-IgG, U/ ml | 105 (84–124) | 114 (89–146) | 0.018* | 116 (98–155) | 112 (83–143) | 0.156 |
| % positive | 93.9% | 99.5% | 0.024# | 98.9% | 100% | 0.436 |
Levels of CMV-IgM, CMV-IgG were significantly increased in IIM patients compared with healthy control groups as was the percentage of CMV-IgM+, CMV-IgG+.
The normal reference of quantitative CMV-IgM, CMV-IgG is 0–22, and 0–14 U/mL, respectively.
*
P < 0.05 (Unpaired Mann–Whitney U test).
#
P <0.05 (Fisher's exact test/chi-square test). The level of CMV-IgM, CMV-IgG median (IQR).